Table 3.
Predictors of SF-36 component 12 weeks after DAA treatment
| Pain | General health | Energy/fatigue | Health Change | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bivariate | Multivariate | Bivariate | Multivariate | Bivariate | Multivariate | Bivariate | Multivariate | |||||||||
| RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | RR (95% CI) | p | |
| Male gender | 1.05 (0.43–2.58) | 1.000 | 3.14 (1.12–8.80) | 0.005 | 6.21 (1.69–22.88) | 0.006 | 1.79 (0.85–3.75) | 0.111 | 2.78 (0.91–8.46) | 0.072 | 2.07 (0.73–5.87) | 0.196 | 0.37 (0.10–1.38) | 0.140 | ||
| Age ≤ 40 year | 0.72 (0.42–1.26) | 0.356 | 0.91 (0.67–1.25) | 0.695 | 1.12 (0.79–1.60) | 0.627 | 1.07 (0.66–1.73) | 0.935 | ||||||||
| University education | 1.03 (0.59–1.77) | 1,000 | 0.96 (0.71–1.29) | 0.901 | 0.95 (0.70–1.30) | 0.871 | 0.83 (0.53–1.29) | 0.511 | ||||||||
| Married versus not married | 1.56 (0.63–3.88) | 0.574 | 1.05 (0.49–2.27) | 0.648 | 0.57 (0.26–1.25) | 0.351 | 1.59 (0.71–3.57) | 0.178 | 1.74 (0.75–4.01) | 0.195 | ||||||
| Married versus Widow/divorce | 1.42 (0.47–4.26) | 0.574 | 1.56 (0.61–4.00) | 0.648 | 0.98 (0.38–2.50) | 0.351 | 2.50 (0.84–7.40) | 0.178 | 2.27 (0.75–6.90) | 0.147 | ||||||
| Regular worker versus non-regular | 1.76 (0.78–3.96) | 0.356 | 0.90 (0.44–1.85) | 0.020 | 1.08 (0.50–2.35) | 0.843 | 1.26 (0.62–2.56) | 0.380 | 0.97 (0.47–2.02) | 0.880 | ||||||
| Regular worker versus not working | 1.42 (0.47–4.26) | 0.356 | 3.69 (1.27–10.71) | 0.020 | 2.52 (0.76–8.39) | 0.132 | 2.00 (0.74–7.37) | 0.380 | 1.26 (0.45–3.56) | 0.880 | ||||||
| CD4 > 500 versus 350–500 | 1.06 (0.36–3.10) | 0.957 | 0.60 (0.23–1.55) | 0.676 | 0.84 (0.33–2.12) | 0.914 | 0.62 (0.24–1.60) | 0.206 | 0.55 (0.20–1.50) | 0.244 | ||||||
| CD4 > 500 versus < 350 | 0.86 (0.36–2.06) | 0.957 | 0.84 (0.39–1.83) | 0.676 | 0.84 (0.39–1.83) | 0.914 | 0.62 (0.28–1.37) | 0.206 | 0.55 (0.23–1.29) | 0.169 | ||||||
| HCV-RNA > 800,000 IU/mL | 0.99 (0.52–1.88) | 1,000 | 0.97 (0.69–1.37) | 1,000 | 0.94 (0.66–1.32) | 0.861 | 0.78 (0.49–1.23) | 0.399 | ||||||||
| Interferon failure | 0.56 (0.15–2.08) | 0.515 | 0.99 (0.58–1.67) | 1,000 | 1.02 (0.60–1.72) | 1,000 | 1.81 (1.11–2.95) | 0.069 | 3.09 (0.96–10.01) | 0.059 | ||||||
| Achieving SVR12 | 0.91 (0.27–3.05) | 1,000 | 0.75 (0.46–1.23) | 0.455 | 1.90 (0.58–6.20) | 0.253 | 0.85 (0.35–2.05) | 0.706 | ||||||||
| Non-smoker | 1.01 (0.59–1.75) | 1,000 | 0.89 (0.66–1.20) | 0.564 | 0.89 (0.66–1.21) | 0.564 | 1.05 (0.69–1.62) | 0.950 | ||||||||
| BMI normal versus underweight | 1.20 (0.40–3.64) | 0.659 | 0.66 (0.24–1.80) | 0.437 | 0.60 (0.22–1.65) | 0.440 | 0.40 (0.15–1.08) | 0.177 | 0.45 (0.16–1.28) | 0.135 | ||||||
| BMI normal versus overweight/obese | 1.54 (0.60–3.98) | 0.659 | 1.37 (0.62–3.02) | 0.437 | 1.26 (0.57–2.77) | 0.440 | 0.90 (0.39–2.06) | 0.177 | 0.68 (0.27–1.69) | 0.403 | ||||||
| Non-IVDU | 1.22 (0.56–2.68) | 0.763 | 0.32 (0.11–0.89) | 0.005 | 0.27 (0.07–1.13) | 0.072 | 0.94 (0.56–1.57) | 1,000 | 1.23 (0.67–2.24) | 0.720 | ||||||
| Fibrosis stage F0–F1 versus F2–F3 | 1.00 (0.37–2.66) | 0.276 | 1.28 (0.55–2.94) | 0.243 | 1.69 (0.70–4.08) | 0.240 | 1,20 (0.52–2.75) | 0.298 | 0.76 (0.32–1.80) | 0.690 | ||||||
| Fibrosis stage F0–F1 versus F4 | 0.50 (0.20–1.22) | 0.276 | 2.06 (0.88–4.85) | 0.243 | 2.85 (1.16–7.00) | 0.023 | 0.55 (0.23–1.32) | 0.298 | 0.72 (0.30–1.71) | 0.690 | ||||||
| Non-anemia | 0.58 (0.33–1.04) | 0.141 | 0.46 (0.19–1.13) | 0.090 | 1.16 (0.75–1.80) | 0.621 | 1,40 (0.84–2,32) | 0.221 | 1.68 (0.68–4.12) | 0.261 | 1.63 (0.79–3.39) | 0.228 | 1.52 (0.52–4.56) | 0.453 | ||
| NNRTI-based versus PI-based ART | 1.76 (0.60–5.16) | 0.402 | 1.17 (0.71–1.93) | 0.674 | 1.14 (0.69–1.88) | 0.771 | 1.85 (0.75–4.53) | 0.212 | 2.47 (0.76–8.00) | 0.132 | ||||||
HCV-RNA: hepatitis C virus ribonucleic acid; SVR12: sustained virological response at 12 weeks post treatment; BMI: body mass index; IVDU: intravenous drug user; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; ART: antiretroviral therapy